Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics

被引:1
|
作者
Ober, Allison J. [1 ]
Dopp, Alex R. [1 ]
Clingan, Sarah E. [2 ]
Curtis, Megan E. [2 ]
Lin, Chunqing [3 ]
Calhoun, Stacy [2 ]
Larkins, Sherry [2 ]
Black, Megan [2 ]
Hanano, Maria [2 ]
Osterhage, Katie P. [4 ]
Baldwin, Laura-Mae [4 ]
Saxon, Andrew J. [5 ,6 ]
Hichborn, Emily G. [7 ]
Marsch, Lisa A. [7 ]
Mooney, Larissa J. [2 ]
Hser, Yih-Ing [2 ]
机构
[1] RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA
[2] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Ctr Community Hlth, Los Angeles, CA USA
[4] Univ Washington, Dept Family Med, Seattle, WA USA
[5] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA
[6] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA
[7] Dartmouth Coll, Ctr Technol & Behav Hlth, Geisel Sch Med, Lebanon, NH USA
基金
美国国家卫生研究院;
关键词
Opioid use disorder (OUD); Medication for opioid use disorder (MOUD); Telemedicine (TM); Primary care; Rural health; Implementation; BUPRENORPHINE-NALOXONE; ASSISTED TREATMENT; COVID-19; BARRIERS; INTERVENTION; ADDICTION; SETTINGS;
D O I
10.1016/j.josat.2023.209194
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Introduction: Opioid overdose deaths are increasing rapidly in the United States. Medications for opioid use disorder (MOUD) are effective and can be delivered in primary care, but uptake has been limited in rural communities. Referral to and coordination with an external telemedicine (TM) vendor by rural primary care clinics for MOUD (TM-MOUD) may increase MOUD access for rural patients, but we know little about perspectives on this model among key stakeholders. As part of a TM-MOUD feasibility study, we explored TM-MOUD acceptability and feasibility among personnel and patients from seven rural primary care clinics and a TM-MOUD vendor.Methods: We conducted virtual interviews or focus groups with clinic administrators (n = 7 interviews), clinic primary care and behavioral health providers (8 groups, n = 30), other clinic staff (9 groups, n = 37), patients receiving MOUD (n = 16 interviews), TM-MOUD vendor staff (n = 4 interviews), and vendor-affiliated behavioral health and prescribing providers (n = 17 interviews). We asked about experiences with and acceptability of MOUD (primarily buprenorphine) and telemedicine (TM) and a TM-MOUD referral and coordination model. We conducted content analysis to identify themes and participants quantitatively rated acceptability of TM-MOUD elements on a 4-item scale.Results: Perceived benefits of vendor-based TM-MOUD included reduced logistical barriers, more privacy and less stigma, and access to services not available locally (e.g., counseling, pain management). Barriers included lack of internet or poor connectivity in patients' homes, limited communication and trust between TM-MOUD and clinic providers, and questions about the value to the clinic of TM-MOUD referral to external vendor. Acceptability ratings for TM-MOUD were generally high; they were lowest among frontline staff.Conclusions: Rural primary care clinic personnel, TM-MOUD vendor personnel, and patients generally perceived referral from primary care to a TM-MOUD vendor to hold potential for increasing access to MOUD in rural communities. Increasing TM-MOUD uptake requires buy-in and understanding among staff of the TM-MOUD workflow, TM services offered, requirements for patients, advantages over clinic-based or TM services from clinic providers, and identification of appropriate patients. Poverty, along with patient hesitation to initiate treatment, creates substantial barriers to MOUD treatment generally; insufficient internet availability creates a substantial barrier to TM-MOUD.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Primary Care of Opioid use Disorder: The End of "the French Model"?
    Dupouy, Julie
    Maumus-Robert, Sandy
    Mansiaux, Yohann
    Pariente, Antoine
    Lapeyre-Mestre, Maryse
    EUROPEAN ADDICTION RESEARCH, 2020, 26 (06) : 346 - 354
  • [42] Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder
    DeRonne, Beth M.
    Wong, Kara R.
    Schultz, Erica
    Jones, Elzie
    Krebs, Erin E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (04) : 354 - 359
  • [43] Medication Treatment and Health Care Use Among Adolescents With Opioid Use Disorder in Ohio
    Chavez, Laura J.
    Bonny, Andrea E.
    Bradley, Katharine A.
    Lapham, Gwen T.
    Cooper, Jennifer
    Miller, William
    Chisolm, Deena J.
    JOURNAL OF ADOLESCENT HEALTH, 2020, 67 (01) : 33 - 39
  • [44] Optimizing Patient Engagement in Treatment for Opioid Use Disorder: Primary Care Team Perspectives on Influencing Factors
    Austin, Elizabeth J.
    Chen, Jessica
    Soyer, Elena
    Idrisov, Bulat
    Briggs, Elsa S.
    Ferro, Lori
    Saxon, Andrew J.
    Fortney, John C.
    Curran, Geoffrey M.
    Moghimi, Yavar
    Blanchard, Brittany E.
    Williams, Emily C.
    Ratzliff, Anna D.
    Ruiz, Monica S.
    Koch, Ulrich
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2024, : 3196 - 3204
  • [45] Barriers for Implementing the Hub and Spoke Model to Expand Medication for Opioid Use Disorder: A Case Study of Montana
    Green, Brandn
    Rhubart, Danielle Christine
    Filteau, Matthew R.
    SUBSTANCE ABUSE-RESEARCH AND TREATMENT, 2021, 15
  • [46] Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice
    Deyo-Svendsen, Mark
    Cabrera Svendsen, Matthew
    Walker, James
    Hodges, Andrea
    Oldfather, Rachel
    Mansukhani, Meghna P.
    JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2020, 11
  • [47] Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations
    Bethany McLeman
    Phoebe Gauthier
    Laurie S. Lester
    Felicity Homsted
    Vernon Gardner
    Sarah K. Moore
    Paul J. Joudrey
    Lisa Saldana
    Gerald Cochran
    Jacklyn P. Harris
    Kathryn Hefner
    Edward Chongsi
    Kimberly Kramer
    Ashley Vena
    Rebecca A. Ottesen
    Tess Gallant
    Jesse S. Boggis
    Deepika Rao
    Marjorie Page
    Nicholas Cox
    Michelle Iandiorio
    Ekow Ambaah
    Udi Ghitza
    David A. Fiellin
    Lisa A. Marsch
    Addiction Science & Clinical Practice, 19
  • [48] Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study
    Emily G. Hichborn
    Owen B. Murray
    Eilis I. Murphy
    Tess E. Gallant
    Sarah K. Moore
    Bethany M. McLeman
    John Saroyan
    Anthony Folland
    Megan Mitchell
    Lisa A. Marsch
    Addiction Science & Clinical Practice, 20 (1)
  • [49] Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations
    McLeman, Bethany
    Gauthier, Phoebe
    Lester, Laurie S.
    Homsted, Felicity
    Gardner III, Vernon
    Moore, Sarah K.
    Joudrey, Paul J.
    Saldana, Lisa
    Cochran, Gerald
    Harris, Jacklyn P.
    Hefner, Kathryn
    Chongsi, Edward
    Kramer, Kimberly
    Vena, Ashley
    Ottesen, Rebecca A.
    Gallant, Tess
    Boggis, Jesse S.
    Rao, Deepika
    Page, Marjorie
    Cox, Nicholas
    Iandiorio, Michelle
    Ambaah, Ekow
    Ghitza, Udi
    Fiellin, David A.
    Marsch, Lisa A.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2024, 19 (01)
  • [50] Rationale, evidence, and steps for implementation of medication for opioid use disorder treatment programs in HIV primary care settings
    Brizzi, Marisa
    Green, Sarah B. B.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2023, 35 (11): : 1760 - 1767